Many investors get distracted by past performance when they buy a fund. But there’s something else to consider that will have a much bigger influence on your returns.
It may feel like there is very little value to be found in the markets. But these three new small-cap investment trusts are betting against that, says Merryn Somerset Webb.
BioPharma Credit, a life-sciences investment trust, offers a tempting yield. But the dangers may be high when the credit cycle turns.
This London-listed Reit lets you invest in the growing consumer markets of an exciting continent, says David Stevenson.
Miton Global hunts for rare treasures in the remoter reaches of the market – all you need to do is buy in, says Max King.
Those who say that passive investing represents the “blind” allocation of capital have a point, says John Stepek. But it’s not like active fund managers were very “active” to begin with.
Haranguing company managers is a lucrative business for those who like to get stuck in, says Max King.
Professional investor Nick Greenwood of selects three investment trusts that are trading at a discount to buy now.
These aircraft-leasing funds were hit by fears over their planes’ resale value. Now, they look cheap.
The broader equity market made little progress in the first half of 2018, but those who followed our investment trust recommendations have reason to be pleased, says Max King.
The world’s problems can be solved – and the Impax Environmental Markets investment trust is well placed to profit from fixing them.